Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Asset disposition
Credit agrmnt [a]
Acq. announced
|
|
Tribute Pharmaceuticals Canada Inc. (TBUFF)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/10/2016 |
8-K
| Quarterly results |
| 02/05/2016 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 02/01/2016 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits|
Docs:
|
"TRIBUTE ANNOUNCES RESULTS OF SHAREHOLDER VOTE MILTON, ONTARIO - February 1, 2016 - Tribute Pharmaceuticals Canada Inc. , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it has received overwhelming shareholder approval of the previously announced plan of arrangement with, among others, Aralez Pharmaceuticals Inc. , which forms part of the pending transaction with POZEN Inc. . Of the votes cast at the Tribute shareholder's meeting held today, approximately 99.81% voted in favour of the special resolution approving the Arrangement. The Company will now apply to the Ontario Superior Court of Justice for a final order approving the Arrangement. The hearing in res..." |
|
| 01/21/2016 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Leading Independent Advisors Recommend that Tribute Shareholders Vote FOR the Transaction MILTON, ONTARIO - 1/21/16 - Tribute Pharmaceuticals Canada Inc. , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that Institutional Shareholder Services and Glass Lewis & Co. have both recommended that Tribute shareholders vote FOR the special resolution to approve the previously announced transaction with Pozen Inc. and combination under Aralez Pharmaceuticals Inc. , to be considered at the upcoming special meeting of Tribute shareholders to be held on February 1, 2016 at 10:00 a.m. at the offices of Fogler, Rubinoff LLP, located at 77 King Street West, Suite 3000, ..." |
|
| 01/11/2016 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits |
| 01/04/2016 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Tribute Pharmaceuticals Receives Notice of Allowance for Canadian Patent Expanding Cambia® Use in Migraine Treatment MILTON, ONTARIO - - 01/04/16 - Tribute Pharmaceuticals Canada Inc. , a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian patent No. 2,632,375, entitled “Diclofenac Formulations and Method of Use.” This patent, which was developed by APR Applied Pharma Research s.a. , a private, international corporation headquartered in Switzerland and focused on the development and commercialization of innovative healthcare products, is licensed exclusively to Tribute in Canada..." |
|
| 12/28/2015 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"TRIBUTE SCHEDULES SPECIAL SHAREHOLDER MEETING FOR MILTON, ONTARIO – December 28, 2015 - Tribute Pharmaceuticals Canada Inc. , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that its special meeting of shareholders in connection with the pending transaction with POZEN Inc. will be held on February 1, 2016 at 10:00 a.m. EST, at the offices of Fogler, Rubinoff LLP at Suite 3000, 77 King Street West, Toronto, Ontario. This meeting is being held to seek shareholder approval of the proposed transaction and related matters. Tribute is expected to mail the meeting materials in early January. Tribute’s shareholders of record as of the close of business on December 31, 20..." |
|
| 12/07/2015 |
8-K
| Asset disposition|
Docs:
|
"Amendment No. 1 to the Agreement and Plan of Merger and Arrangement, by and among Pozen, Tribute, Former Parent, Holdings, Former US Merger Sub, US Merger Sub, and Can Merger Sub",
"Amendment No. 2 to the Agreement and Plan of Merger and Arrangement, by and among Pozen, Tribute, Former Parent, Holdings, US Merger Sub, Can Merger Sub, and Parent",
"Second Amended and Restated Debt Facility Agreement, by and among Parent, Pozen, Tribute, and the Lenders",
"Second Amended and Restated Registration Rights Agreement, by and among Parent and the Lenders",
"Amended and Restated Share Subscription Agreement, by and among Parent, Former Parent, Tribute, Pozen, Purchaser and the Investors",
"POZEN AND TRIBUTE ANNOUNCE PLAN TO PROCEED WITH MERGER TO FORM ARALEZ PHARMACEUTICALS" |
|
| 11/23/2015 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 11/09/2015 |
8-K
| Other Events, Financial Statements and Exhibits |
| 11/09/2015 |
8-K
| Quarterly results|
Docs:
|
"Tribute Announces Third Quarter 2015 Results -Revenue Up 133%, EBITDA Up 281% over Comparative Period- MILTON, ONTARIO – November 9, 2015 - Tribute Pharmaceuticals Canada Inc. , a diversified healthcare company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the third quarter ended September 30, 2015. Unless otherwise indicated, all dollar amounts included herein are stated in Canadian dollars. The Company's financial statements and management report are available at www.sedar.com, www.sec.gov and at www.tributepharma.com. Financial Results Highlights Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Total Revenues $9,007,850 $21,02..." |
|
| 11/09/2015 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 10/30/2015 |
8-K
| Financial Statements and Exhibits |
| 08/17/2015 |
8-K
| Quarterly results|
Docs:
|
"Tribute Pharmaceuticals Announces Second Quarter 2015 Results -Revenue Up 59%, Gross Profit Up 101% over Comparative Period- MILTON, ONTARIO – August 17, 2015 - Tribute Pharmaceuticals Canada Inc. , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the second quarter ended June 30, 2015. Unless otherwise indicated, all dollar amounts included herein are stated in Canadian dollars. The Company's financial statements and management report are available at www.sedar.com, www.sec.gov and at www.tributepharma.com. Financial Results Highlights Three Months Ended Six Months Ended June 30, 2015 Total Revenues $ 6,429,500 $ 12,021,8..." |
|
| 06/22/2015 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...|
Docs:
|
"Share Purchase Agreement, by and among Tribute Pharmaceuticals Canada Inc. and the shareholders of Medical Futures Inc",
"Agency Agreement, by and among Tribute Pharmaceuticals Canada Inc., and KES 7 Capital Inc., Bloom Burton & Co. Ltd, Mackie Research Capital Corporation, Laurentian Bank Securities Inc. and Dundee Capital Markets Ltd",
"Promissory Note issued in connection with the Acquisition on June 16, 2015",
"Form of Debenture for the Debenture Offering that closed on June 16, 2015",
"Tribute Pharmaceuticals Announces Acquisition of Medical Futures Inc., a Canadian Specialty Pharmaceutical Company ● Includes Canadian Rights to Durela®, Proferrin® and 13 Additional Products MILTON, ONTARIO - Tribute Pharmaceuticals Canada Inc. , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that it has acquired Medical Futures Inc. in a transaction valued at $25 million. Financial terms of the deal include the payment of: $8.3 million in cash on closing; $5 million through the issuance of 3,723,008 common shares in the capital of Tribute; and, $5 million in the form of a one year term promissory note bearing interest at 8% annually convertible at..." |
|
| 06/12/2015 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits|
Docs:
|
"Agreement and Plan of Merger and Arrangement, among Pozen, Tribute, Parent, Ltd2, US Merger Sub and Can Merger Sub",
"Agreement and Plan of Merger and Arrangement, among Pozen, Tribute, Parent, Ltd2, US Merger Sub and Can Merger Sub",
"Form of Tribute Support Agreement",
"Form of Tribute Support Agreement",
"Facility Agreement, among the Borrower, Pozen, and the Lenders",
"Facility Agreement, among the Borrower, Pozen, and the Lenders",
"Share Subscription Agreement, among Tribute, Pozen, Purchaser, Parent and the Investors",
"Share Subscription Agreement, among Tribute, Pozen, Purchaser, Parent and the Investors" |
|
| 06/08/2015 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits |
| 05/28/2015 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Asset Purchase Agreement, by and among Tribute Pharmaceuticals International Inc., Mutual Pharmaceutical Company, Inc. and Sun Pharmaceutical Industries, Inc",
"Asset Purchase Agreement, by and among Tribute Pharmaceuticals International Inc., Mutual Pharmaceutical Company, Inc. and Sun Pharmaceutical Industries, Inc",
"Agency Agreement, by and among Tribute Pharmaceuticals Canada Inc., Dundee Securities Ltd., KES 7 Capital Inc. and Bloom Burton & Co. Inc",
"Agency Agreement, by and among Tribute Pharmaceuticals Canada Inc., Dundee Securities Ltd., KES 7 Capital Inc. and Bloom Burton & Co. Inc",
"Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor® and Commercial Expansion into U.S. Market ● William Maichle Hired as President of U.S. Operations MILTON, ONTARIO - Tribute Pharmaceuticals Canada Inc. , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that its wholly owned subsidiary, Tribute Pharmaceuticals International Inc., a Barbados corporation, has acquired the U.S. rights to Fibricor® and its related authorized generic from a wholly owned step-down subsidiary of Sun Pharmaceutical Industries Ltd. . Financial terms of the deal include the payment of US$10 million as follows: US$5 million on closing; US$2 million payable...",
"Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor® and Commercial Expansion into U.S. Market ● William Maichle Hired as President of U.S. Operations MILTON, ONTARIO - Tribute Pharmaceuticals Canada Inc. , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that its wholly owned subsidiary, Tribute Pharmaceuticals International Inc., a Barbados corporation, has acquired the U.S. rights to Fibricor® and its related authorized generic from a wholly owned step-down subsidiary of Sun Pharmaceutical Industries Ltd. . Financial terms of the deal include the payment of US$10 million as follows: US$5 million on closing; US$2 million payable..." |
|
| 05/21/2015 |
8-K
| Other Events, Financial Statements and Exhibits |
| 05/14/2015 |
8-K
| Quarterly results|
Docs:
|
"Tribute Pharmaceuticals Announces First Quarter 2015 Results -Revenue Up 60%, EBITDA Up 116% Over Comparative Period- MILTON, ONTARIO – May 12, 2015 - Tribute Pharmaceuticals Canada Inc. , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the first quarter ended March 31, 2015. Unless otherwise indicated, all dollar amounts included herein are stated in Canadian dollars. The Company's financial statements and management report are available at www.sedar.com, www.sec.gov and at www.tributepharma.com. Financial Results Highlights Three Months Ended March 31, 2015 Three Months Ended March 31, 2014 Revenue $ 5,592,297 $ 3,493,55..." |
|
| 03/04/2015 |
8-K
| Unregistered Sales of Equity Securities |
| 03/03/2015 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits|
Docs:
|
"Tribute Pharmaceuticals Announces Strong 2014 Fourth Quarter and Year End Results -4th quarter Revenue up 70.5% and EBITDA up 217% over comparative periods- MILTON, ONTARIO - March 3, 2015 - Tribute Pharmaceuticals Canada Inc. , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the fourth quarter and year ended December 31, 2014. Unless otherwise indicated, all dollar amounts included herein are stated in Canadian dollars. The Company's financial statements and management report are available at www.sedar.com, www.sec.gov and at www.tributepharma.com. Financial Results Highlights Three Months Ended December 31, 2014 Twelve M..." |
|
| 02/02/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/27/2015 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 11/10/2014 |
8-K
| Quarterly results|
Docs:
|
"Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014 MILTON, ONTARIO - - Tribute Pharmaceuticals Canada Inc. , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced financial results for its third quarter ending September 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles . On October 2, 2014, subsequent to the quarter ended September 30, 2014, the Company entered into an asset purchase agreement, license agreement and supply agreement with Novartis AG and Novartis Pharma AG pursuant..." |
|
| 11/05/2014 |
8-K
| Other Events, Financial Statements and Exhibits |
| 10/08/2014 |
8-K
| Acquisition/merger/asset purchase announced |
| 09/25/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 08/11/2014 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 08/06/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 08/05/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 07/16/2014 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu... |
| 06/27/2014 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 05/30/2014 |
8-K
| Other Events, Financial Statements and Exhibits |
|
|
|